Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
OTC Stocks Trading News: Fannie Mae, Immune Pharmaceuticals, Inc. Cannabis Sativa, Inc. United Cannabis Corp, Cynk Technology Corp.
PR Newswire Europe - Thu Jul 10, 7:01AM CDT
LONDON, July 10, 2014 /PRNewswire/ --
IMMUNE Partners With Patient Community Group LYFEBULB
GlobeNewswire - Wed Jun 25, 1:30AM CDT
Lyfebulb, an organization dedicated to helping people achieve their optimal lifestyle by addressing general and chronic health concerns, and Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) co-hosted the third Lyfebulb event on June 19th at Brasserie Ruhlmann in New York. The event provided an opportunity for guests to connect and learn about emerging and personalized therapies in Crohn's and Colitis Disease, also known as Inflammatory Bowel Disease (IBD). The event's host committee included Lyfebulb founder and renowned health and wellness expert, Dr. Karin Hehenberger, Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, and Dr. James Aisenberg, distinguished gastroenterologist and Associate Clinical Professor of Medicine at The Mount Sinai Hospital.
Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President
GlobeNewswire - Fri Jun 06, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
Liver Failure - Pipeline Review, H1 2014: 6 Companies Mentioned
M2 - Thu May 29, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vx7phw/liver_failure) has announced the addition of the "Liver Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Liver Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Alfact Innovation - Conatus Pharmaceuticals - Digna Biotech - Immune Pharmaceuticals - Pharmicell - Silence Therapeutics - Ventria Bioscience For more information visit http://www.researchandmarkets.com/research/vx...er_failure
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Hodgkin Lymphoma - Pipeline Review, H1 2014: 25 Companies Profiled
M2 - Thu May 29, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mq7w54/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - 4SC AG - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Cell Therapeutics, Inc. - Dynavax Technologies Corporation - Gamida Cell Ltd. - Gilead Sciences, Inc. - Immune Pharmaceuticals, Inc. - Incyte Corporation - Janssen Research & Development, LLC - MABLife S.A.S - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pharmedartis GmbH - Philogen S.p.A. - Plexxikon Inc. - Rhizen Pharmaceuticals SA - Seattle Genetics, Inc. - Sigma-Tau Pharmaceuticals, Inc - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Syndax Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mq...n_lymphoma
Immune Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 21, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (Nasdaq:IMNP) ("Immune" or "the Company"
Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
IMMUNE Pharmaceuticals to Present at the 16th BIO CEO & Investor Conference
Marketwire - Thu Feb 06, 4:45PM CST
IMMUNE Pharmaceuticals Inc. (OTCQX: IMNP) (NASDAQ: IMNP) announced today that Daniel Teper, Chairman and Chief Executive Officer, will be presenting at the 16th annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 11:30AM local time at the Waldorf Astoria, Room Duke of Windsor, in New York.
LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals
Marketwire - Tue Dec 10, 7:01AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer. Immune Pharmaceuticals' lead development program is bertilimumab, currently in Phase II clinical trials for treatment of ulcerative colitis (UC), Crohn's disease (CD) and bullous pemphigoid (BP), an orphan, autoimmune dermatological condition. Data from trials of bertilimumab in BP and CD are expected in mid-2014, and data from the UC trial is expected in the first half of 2015.